Merck & co inc（MRK.US AI Earnings Summary）
MRK AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
New third-party drugs have surged to become operational pillars, and earnings expectations have been raised simultaneously, demonstrating high visibility in the business transformation.
- Stock Price Reaction: Merck announced its third-quarter financial results. Boosted by outstanding adjusted earnings per share and revenue performance, along with an upward revision of the full-year profit outlook, the stock price once rose 4.82% to $147.73 (Pre-market ET, 10/29).
- Against Market Expectations: No market consensus data available; no comparison or judgment made.
- Against Own Previous Guidance: All targets met. Full-year revenue fell in the upper-middle range of the guidance; full-year Non-GAAP EPS was approximately 1.3% higher than the upper limit of guidance; Non-GAAP gross margin was 81.4%, higher than the guidance of approximately 81%.
- In One Sentence: Merck raised its full-year profit forecast driven by the steady growth of KEYTRUDA and the strong ramp-up of new drugs like WINREVAIR, with the market responding by a 4.82% pre-market gain to $147.73 (ET 10/29).
Quarterly Highlights
The full-scale explosion of the new product lineup is the most noteworthy structural shift this quarter—quarterly revenue from newly launched products leaped from $800M in the same period last year to $2.2B, a year-over-year increase of nearly 1.75 times, indicating that MRK's business transformation has moved from 'expectation' to 'realization'.
Full-year outlook raised, own guidance higher than previous upper limit: CFO Caroline Litchfield announced that the full-year Non-GAAP revenue forecast has been narrowed and raised to $66.8B–$67.3B, falling in the upper-middle range of the previous guidance; the full-year Non-GAAP EPS forecast was simultaneously raised to $2.77–$2.82, approximately 1.3% higher than the upper limit of last quarter's guidance. This is the second time MRK has raised its full-year forecast this fiscal year, showing business execution continues to exceed planning.
KEYTRUDA family exceeds $8.6B, subcutaneous formulation KEYTRUDA QLEX contributes $830M in a single quarter: The KEYTRUDA family (including KEYTRUDA and KEYTRUDA QLEX) grew 6% year-over-year at constant currency to approximately $8.6B. Growth momentum came from increased penetration in early-stage cancers (cervical, breast, head and neck) and the continued ramp-up of the combination therapy with PADCEV in urothelial carcinoma. KEYTRUDA QLEX adoption has continued to climb since obtaining a permanent J-code on April 1; management reiterated the target of 30%–40% conversion rate in the US market by the end of 2027.
WINREVAIR quarterly sales reached $694M, up 94% YoY, becoming the fastest-growing core product: Global sales for the pulmonary arterial hypertension (PAH) treatment WINREVAIR grew 94% YoY. In the US market, approximately 1,600 new patients obtained prescriptions this quarter, with cumulative prescriptions exceeding 38,000. The FDA also approved a label update for WINREVAIR this quarter to include results from the Phase 3 HYPERION trial, supporting its use earlier in newly diagnosed PAH patients and further expanding the potential patient population.
sac-TMT achieves first global milestone in Phase 3 endometrial cancer trial: Detailed Phase 3 data for sac-TMT (a TROP2-targeted antibody-drug conjugate or ADC) from the TroFuse-005 trial was presented at the ESMO Congress. Compared to the chemotherapy group, median overall survival improved by nearly 7 months, and the risk of death was reduced by 32%. Research Head Dean Li stated this is the first formal readout of MRK's global TroFuse program (totaling 17 Phase 3 trials). The FDA PDUFA date is set for June 15, and a priority review voucher will be applied for to accelerate the review.
intismeran personalized mRNA cancer vaccine Phase 3 data marks a milestone: Developed in collaboration with Moderna (Ticker: MRNA), the personalized neoantigen therapy intismeran autogene, used as adjuvant treatment for postoperative melanoma in the INTerpath-001 trial, significantly improved recurrence-free survival and distant metastasis-free survival compared to standard KEYTRUDA monotherapy. CEO Rob Davis noted that this data makes intismeran's commercial potential better than originally planned, and active discussions with the FDA regarding the application process are underway.
GARDASIL up 14% to $2B, US benefited from large CDC purchases: GARDASIL sales grew 14% YoY this quarter, with the US market up 18%, primarily benefiting from a one-time large purchase by the CDC and price increases; international markets grew 6%. Notably, the vaccine business saw a total purchasing timing benefit of $300M this quarter (mainly GARDASIL), of which $50.0M is expected to reverse in Q4, and the remaining $250M will reverse in 2027, as pre-warned by management.
WELIREG up 58% to $307M, renal cell carcinoma indications continue to expand: Sales for the HIF-2α inhibitor WELIREG grew 58% YoY, driven by increased use in previously treated renal cell carcinoma patients in the US, new adjuvant treatment indications, and continued international promotion. This quarter, the FDA also approved WELIREG in combination with LENVIMA for previously treated renal cell carcinoma, further expanding its indication footprint.
Combined revenue of newly launched products leaped from $800M to $2.2B: Newly launched products including WINREVAIR, OHTUVAYRE, ENFLONSIA, and LIPFENDRA contributed a total of $2.2B this quarter, up nearly 1.75 times from $800M in the same period last year, confirming management's repeated emphasis that "business transformation is being realized." OHTUVAYRE (COPD maintenance) contributed $184M, and ENFLONSIA (RSV prevention) contributed $187M, both reflecting seasonal demand and inventory building.